dc.creatorRIOS, Danyelle R. A.
dc.creatorRODRIGUES, Edna T.
dc.creatorCARDOSO, Ana P. Z.
dc.creatorMONTES, Marlise B. A.
dc.creatorFRANCESCHINI, Silvio A.
dc.creatorTOLOI, Maria R. T.
dc.date.accessioned2012-10-20T03:22:12Z
dc.date.accessioned2018-07-04T15:35:35Z
dc.date.available2012-10-20T03:22:12Z
dc.date.available2018-07-04T15:35:35Z
dc.date.created2012-10-20T03:22:12Z
dc.date.issued2008
dc.identifierNUTRITION, v.24, n.2, p.120-126, 2008
dc.identifier0899-9007
dc.identifierhttp://producao.usp.br/handle/BDPI/28237
dc.identifier10.1016/j.nut.2007.10.009
dc.identifierhttp://dx.doi.org/10.1016/j.nut.2007.10.009
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1624881
dc.description.abstractObjective: We evaluated the effects of soy isoflavone supplementation on hemostasis in healthy postmenopausal women. Methods: In this double-blinded, placebo-controlled study, 47 postmenopausal women 47-66 y of age received 40 mg of soy isoflavone (n = 25) or 40 mg of casein placebo (n = 22) once a day for 6 mo. Levels of factors VII and X. fibrinogen, thrombin-antithrombin complex, prothrombin fragments I plus 2, antithrombin, protein C, total and free protein S, plasminogen, plasminogen activator inhibitor-1, and D-dimers were measured at baseline and 6 mo. Urinary isoflavone concentrations (genistein and daidzein) were measured as a marker of compliance and absorption using high-performance liquid chromatography. Baseline characteristics were compared by unpaired Student`s t test. Within-group changes and comparison between the isoflavone and casein placebo groups were determined by a mixed effects model. Results: The levels of hemostatic variables did not change significantly throughout the study in the isoflavone group; however, the isoflavone group showed a statistically significant reduction in plasma concentration of prothrombin fragments I plus 2; both groups showed a statistically significant reduction in antithrombin, protein C, and free protein S levels. A significant increase in D-dimers was observed only in the isoflavone group. Plasminogen activator inhibitor-l levels increased significantly in the placebo group. However, these changes were not statistically different between groups. Conclusion: The results of the present study do not support a biologically significant estrogenic effect of soy isoflavone on coagulation and fibrinolysis in postmenopausal women. However, further research will be necessary to definitively assess the safety and efficacy of isoflavone. (D 2008 Elsevier Inc. All rights reserved.
dc.languageeng
dc.publisherELSEVIER SCIENCE INC
dc.relationNutrition
dc.rightsCopyright ELSEVIER SCIENCE INC
dc.rightsrestrictedAccess
dc.subjectcoagulation
dc.subjectfibrinolysis
dc.subjectsoy isoflavone
dc.subjectpostmenopausal women
dc.titleEffects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución